Pancreatic Cancer Research

ResearcherThe University of AdelaideNo recent work listed

Timothy Jay Price

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3922-2693; OpenAlex author ID A5061460550. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 0, last author 3)
Trials
1
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers, 1 trial · 2023: 2 papers

Papers 6

  1. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  2. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Last author DOI 10.1080/14737140.2023.2270161↗
  3. Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma… Last author DOI 10.1016/s2468-1253(22)00167-4↗
  4. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  5. Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002065↗
  6. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … Last author DOI 10.1080/14737140.2017.1369882↗

Trials 1

  1. The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Study chair NCT05042128↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Dean · 1 shared trial, 2022 · strength 0.49
  2. Christos Stelios Karapetis · 3 shared papers, 2022–2023 · strength 0.39
  3. Lorraine A. Chantrill · 3 shared papers, 2017–2023 · strength 0.32
  4. Andrew Peter Dean · 2 shared papers, 2022–2023 · strength 0.31
  5. Amitesh Chandra Roy · 2 shared papers, 2022 · strength 0.26
  6. Niall Christopher Tebbutt · 2 shared papers, 2022–2023 · strength 0.25
  7. Barbara Geerinckx · 1 shared paper, 2023 · strength 0.20
  8. Timon Vandamme · 1 shared paper, 2023 · strength 0.20
  9. Marc Peeters · 1 shared paper, 2023 · strength 0.20
  10. David Goldstein · 2 shared papers, 2017–2022 · strength 0.19
  11. Florian Lordick · 2 shared papers, 2017–2022 · strength 0.19
  12. Eva Segelov · 2 shared papers, 2017–2022 · strength 0.19
  13. Ian Chau · 2 shared papers, 2017–2022 · strength 0.19
  14. Nimit Singhal · 1 shared paper, 2022 · strength 0.14
  15. Nick Pavlakis · 1 shared paper, 2022 · strength 0.13
  16. Trevor Leong · 1 shared paper, 2022 · strength 0.13
  17. Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13
  18. Mike Nguyen · 1 shared paper, 2022 · strength 0.13
  19. Daniel John Renouf · 1 shared paper, 2022 · strength 0.13
  20. Joanna Lee · 1 shared paper, 2023 · strength 0.12
  21. Val Gebski · 1 shared paper, 2023 · strength 0.12
  22. Matthew Burge · 1 shared paper, 2023 · strength 0.12
  23. Chris Lomma · 1 shared paper, 2023 · strength 0.12
  24. Marion Harris · 1 shared paper, 2023 · strength 0.12
  25. Belinda Lee · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.